Mecamylamine-Smoker

Mecamylamine-Non-Smoker

Placebo-Smoker

Placebo- Non-Smoker

Total

Sex: Female, Male

Race/Ethnicity, Customized

Veteran Status

Data were calculated as number of heavy drinking days (heavy drinking days is defined as 5 drinks on a single occasion for men and 4 for women) average during 90 days of treatment.

Mecamylamine- Smokers

Mecamylamine- Non-Smoker

Percent Heavy Drinking Days During Active Treatment Phase

The OCDS is a 14-item (rated 0-4), self-administered questionnaire for characterizing and quantifying the obsessive and compulsive cognitive aspects of craving and heavy (alcoholic) drinking, such as drinking-related thought, urges to drink, and the ability to resist those thoughts and urges. A higher total score indicates higher craving and ranges from 0-48.

Mecamylamine

Placebo

Self-report Weekly Craving Via Obsessive Compulsive Drinking Scale (OCDS)

Questionnaire of smoking urges (QSU). It has 32 questions that range from 1 to 7, there are 8 questions per sub-scale. The total range is 32 to 224. Each sub-scale ranges from 8- 56, with a higher score indicating higher craving.

Self-report Weekly Smoking Craving

self-report from only the smoking population for cigarettes per day

Self-report Average Number of Cigarettes Per Day

Mecamylamine- Smoker

Mecamylamine Non-Smoker

Placebo Smoker

Placebo Non-Smoker

Overall Study

Dr. Elizabeth Ralevski

Mecamylamine Smoker

Alcoholism

mecamylamine

VA Connecticut Healthcare System

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

Yale University

pyloric stenosis

dopamine

pyloric stenosis/dopamine

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen